Progesterone Receptor Mouse anti-Human, eFluor 660, Clone: KMC912, eBioscience™

Mouse Monoclonal Antibody

Overview
Brand: Affymetrix eBioscience

Manufacturer Part Number: 50-9764-80

Code: NEW

Additional Details:
Additional Details: Weight: 0.09500kg



Disclaimers: For Research Use Only.

Product Code. 15500127

Quantity Price
1 £ 67.82 / 25µg
Estimated Shipment date
from Supplier 03-04-2017
Add to basket


Description and Specification

Specification

Monoclonal or Polyclonal Monoclonal
Applications Flow Cytometry (Intracellular Staining)
Applications Immunocytochemistry
Applications Immunohistochemistry (Formalin/Paraffin)
Applications Microscopy
Regulatory Status RUO
Clone KMC912
Isotype IgG1
Host Species Mouse
Formulation aqueous buffer, 0.09% sodium azide, may contain carrier protein/stabilizer
Quantity 25μg
Antigen Progesterone Receptor
Storage Requirements Store at 2-8°C. Do not freeze. Light-sensitive material.
Concentration 0.2mg/mL
Gene Alias PR, PgR
Format Conjugated
Species Reactivity Human
Conjugate eFluor 660
Primary or Secondary Primary

This KMC912 monoclonal antibody reacts with human progesterone receptor (PgR, PR), a member of a superfamily of nuclear receptors that are ligand-dependent transcriptional regulators. The human PgR exists in alpha and beta forms, 94kDa and 120kDa respectively. In most human cells, the alpha and beta forms are expressed at similar levels and predominately form heterodimers. Progestin binding to PgR causes a conformational change, allowing dissociation of bound chaperone proteins and subsequent dimerization with either PgRa or PgRb. Following activation, dimerized PgR can directly bind to DNA through progestin response elements (PRE) leading to chromatin remodeling and subsequent downregulation or transcription of the target gene.The PgR plays a key role in controlling gene expression in breast, uterine, brain, and cardiovascular tissue during development. The presence of the PgR in breast tissue is indicative of improved survival and a better response to endocrine therapy. In breast and endometrial cancer progression, a predominance of either the alpha or beta form occurs, suggesting disregulation in the PgRa:PgRb ratio is an early event in cancer. In cases of ductal carcinoma in situ and invasive ductal carcinoma, there is predominance of the alpha form while in uterine cancer a loss of either form is common.